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ABSTRACT
According to the sequential metastasis model, aggressive mesenchymal (M)
metastasis-initiating cells (MICs) are generated by an epithelial-mesenchymal
transition (EMT) which eventually is reversed by a mesenchymal-epithelial
transition (MET) and outgrowth of life-threatening epithelial (E) macrometastases.
Paradoxically, in breast cancer M signatures are linked with more favorable outcomes
than E signatures, and M cells are often dispensable for metastasis in mouse models.
Here we present evidence at the cellular and patient level for the cooperation
metastasis model, according to which E cells are MICs, while M cells merely support
E cell persistence through cooperation. We tracked the fates of co-cultured E and
M clones and of fluorescent CDH1-promoter-driven cell lines reporting the E state
derived from basal breast cancer HMLER cells. Cells were placed in suspension state
and allowed to reattach and select an EMT cell fate. Flow cytometry, single cell and
bulk gene expression analyses revealed that only pre-existing E cells generated E
cells, mixed E/M populations, or stem-like hybrid E/M cells after suspension and that
complete EMT manifest in M clones and CDH1-negative reporter cells resulted in loss
of cell plasticity, suggesting full transdifferentiation. Mechanistically, E-M coculture
experiments supported the persistence of pre-existing E cells where M cells inhibited
EMT of E cells in a mutual cooperation via direct cell-cell contact. Consistently, M
signatures were associated with more favorable patient outcomes compared to E
signatures in breast cancer, specifically in basal breast cancer patients. These findings
suggest a potential benefit of complete EMT for basal breast cancer patients.

INTRODUCTION

Metastatic tumors are thought to originate from a small
population of stem-like cells within the primary tumor,
termed cancer stem cells (CSCs), which due to their
capacity of self-renewal and plasticity [2] can initiate
the metastatic cascade requiring invasion, migration,

While most primary breast tumors are successfully
eliminated by surgery, metastasis remains incurable
and accounts for the vast majority of patient deaths [1].
www.oncotarget.com
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intravasation, survival of detachment and anoikis
resistance in the circulation, extravasation and formation of
epithelial macrometastases. Accordingly, CSC enrichment
in primary tumors can predict poor patient outcomes
[3]. The notion of the CSC-concept was soon combined
with the older idea of EMT, during which epithelial (E)
carcinoma cells with cobble-stone like morphology
convert to a fibroblast-like mesenchymal (M) type of
cell that can complete the initial steps of the metastatic
cascade. Indeed, in the context of luminal epithelial
cell lines of mammary gland tissue or tumors, such as
HMLE, HMLER, and MCF7, the M cell-type has more
CSC-like properties than the epithelial bulk population
[4, 5]. However, in the context of basal, mesenchymal
cell lines, more CSC-like properties were detected in the
adhesion–dependent E population [6–9]. The concept of
stemness of an intermediate E/M state can explain contextdependency and has been supported experimentally at the
cell population level indicating a mixture and cooperation
of E and M cells and is manifested at single cell level in
the existence of a hybrid E/M cell type that co-expresses E
and M gene signatures in vitro and in vivo [10–15], and has
been predicted by theoretical models [16]. Consistently,
co-expression of E and M-specific gene signatures in
patient tumors, either due to mixture or presence of the
hybrid cells, predicts poor survival in diverse breast cancer
subtypes [12]. However, to date the stem-like intermediate
E/M state remains untargetable due to the absence of
specific markers, in comparison to the better defined
differentiated E or differentiated M states, and the cellular
origin of hybrid E/M cells remains unclear.
Previously, two competing metastasis models have
been proposed, where metastases are either caused by (1)
individual M cells establishing new metastatic tumors
(as CSCs or MICs) according to the popular sequential
metastasis model or (2) by E cells acting as MICs with
cooperating M cells as supporting cells, as proposed by
the cooperation metastasis model.
The sequential metastasis model (1) assumes
that the metastatic process is initiated by an EMT [17],
generating individual aggressive M cells [18]. Since lifethreatening proliferating macrometastases typically have
epithelial morphology and are carcinoma, often exhibiting
features of normal differentiated breast epithelium, it
has been postulated that for colonization and expansion
at the new site the individual M cell must reverse to the
epithelial state in a process referred to as mesenchymalto-epithelial-transition (MET) [17, 19, 20]. This process
implies plasticity of M cells. However, experimental
validation of complete MET of individual cells in vivo is
still lacking [21, 22]. In support of MET, or reversibility
of EMT, we recently demonstrated in vitro that clonal
M cells from the tumorigenic breast cell line HMLER
cultured as stem cell enriched mammospheres (MS) could
undergo partial MET and generated individual hybrid E/M
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cells [12], but their stability remained unclear. However,
several experimental observations suggest that complete
EMT is irreversible because sustained and complete EMT
induction ablates cellular phenotypic plasticity in vitro
[9, 23–27]. Accordingly, in mice continuous induction of
EMT decreases incidence of epithelial metastasis [26, 28].
Further, in vitro findings show that single cell-derived M
clones from HMLER cells are not plastic [12, 29]. Finally,
in vivo cell tracking in mice revealed that EMT and thus M
cells did not form lung metastases in breast and pancreatic
cancer [30, 31], further questioning if M cells are MICs.
Consistent with the observed absence of M
cell plasticity, the alternative cooperation metastasis
model (2), originally termed cooperativity theory [32],
proposes that M cells mainly support E cells by cell-cell
cooperation, and that epithelial metastases are directly
derived from pre-existing E cells, implying that MICs
are epithelial cells. Hence, metastasis would not require
MET plasticity of individual M cells. Direct support for
the cooperation metastasis model comes from reports that
in mice coinjection of E and M cells increases distant
metastasis formation derived from pre-existing E cells
[6, 33, 34]. Thus, increased stemness and mammosphere
formation of cooperating HMLER E and M cells, and of
the mixed E/M state at the population level are consistent
with the cooperation metastasis model [12]. The intriguing
consequence of M cells being merely supporting cells
for E MICs has not been examined in detail yet but
would suggest that successful therapeutic induction of
complete EMT beyond the intermediate E/M state might
transdifferentiate epithelial cancers into a non-cancer
M state, and possibly irreversibly eliminate E MICs.
However, the cellular mechanism for how cooperation
between E and M cells prevents detachment-induced
anoikis and EMT plasticity of E cells remains unclear.
To directly contrast the two metastasis models with
either M or E cells being MICs, we combined in vitro and
in silico strategies. In the in vitro studies using clonal E and
M monocultures and E/M cocultures we studied whether
upon detachment it is the M cells that underwent MET or
the E cells that persisted and resisted detachment-induced
anoikis, thereby initiating premetastatic E populations. To
this end, we used the breast-derived heterogeneous basal
HMLER cell line [29, 35], that contains both E (CD24+/
CD44–) and M (CD24–/CD44+) cell populations. Using
publicly available breast cancer patient data, we compared
the association of E versus M signatures with poor survival
and metastases.
Together both our in vitro and patient data are in
line with the cooperation metastasis model: we show in
vitro that pre-existing E cells were required to generate E
subpopulations and were supported by cooperation with
transdifferentiated M cells. Consistently, in breast cancer
patients, the expression of E signatures alone or together
with M signatures predicted worse or equal outcomes than
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pure M signatures, specifically for basal breast cancer
patients, suggesting that E cells are the MICs.

replating to adhesion culture (Supplementary Figure 1A)
should maintain at least some E signature expression and
an intermediate E/M state. Surprisingly, already 24 hours
following reattachment (and thereafter) the intermediate
E/M mammosphere cultures derived from M4 cells had
completely lost the E signature and regained pure M
signature gene expression. This was suggestive of complete
EMT of M4 cells upon readhesion back into an M state
resembling that of the adherent source M cells from the
M4 clone (Figure 1A). By contrast, replated HP-derived
mammosphere cultures did not change gene expression
pattern relative to that of the suspension cultures, and
maintained their intermediate E/M state when analyzed at
6 hours, 24 hours and even ten days past replating.
To test the validity of these observations for other
cell lines, we compared the gene expression profiles of
adherent versus replated cultures of multiple HMLER
M and E clones, as well as HP cells of different freezing
passages. Gene expression profiles of these cells are
visualized in a principal component analysis (PCA)
that uses E and M signature gene expression values
(Figure 1B). HMLER_E and HMLER_M signatures
were originally defined by genes that discriminate most
strongly between adherent HMLER E and M clones. The
PCA placed adherent E and M clones to opposite ends of
principal component 1 (PC1), while suspension cultures of
either origin were located in the intermediate state between
E and M states. Interestingly, in the PCA the M4 clones
displayed a rapid, replating-induced reversion back to the

RESULTS
The suspension-induced intermediate E/M gene
expression state is unstable in M cells upon
readhesion, but stable in E cells
To form macrometastases cancer cells need to
detach from the primary tumor, survive in suspension,
and eventually readhere to a secondary site and express
epithelial genes. To test the potential of M cells to
undergo MET during the metastatic process, we used
(bulk) mRNA expression profiling to assess the stability
of the intermediate E/M state generated by M cells
during suspension mammosphere culture, using the
single cell-derived HMLER M clone M4, which only
contained CD24–/CD44+ (M) cells but no CD24+/
CD44– (E) cells [12]. For comparison, and to test the
alternative cooperation metastasis model with E cells
as MICs, we tested the parental HMLER cell line (HP)
containing mostly CD24+/CD44– E cells under the same
conditions. As recently demonstrated, both HP and M4
cells converged to the intermediate E/M state as assessed
by gene expression analysis using 150 previously defined
epithelial (E_HMLER) and mesenchymal (M_HMLER)
specific gene sets [12] (Figure 1A). Since life-threatening
metastases are epithelial and adherent we reasoned that

Figure 1: Stability of the intermediate E/M state in epithelial but not in mesenchymal cell lines. (A) Heatmap of relative

gene expression as measured in biological replicate arrays from HP and M4 cells that were grown in adhesion (adh), suspension as
mammospheres (MS) and replated for the indicated times from 6 to 240 hours (re6, re24, re96, re240). Expression of indicated E_HMLER
and M_HMLER (150) signatures are shown. (B) Principal component analysis (PCA) of gene expression arrays from M4 and HP cell
lines in (A) and additional HP cell replicates, HMLER-derived E and M single cell clones cultured in adhesion and after replating using
E_HMLER (150) and M_HMLER (150) signatures. Arrows in gray (HP) and blue (M4) indicate state changes of populations between
adhesion, mammospheres and replating. All experiments shown were done in biological replicates (at least duplicates).
www.oncotarget.com
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original M state along PC1, suggesting complete EMT and
instability of the M-derived E/M state in suspension.
All additional M clones (M1, M2, M3, M5) exhibited
the same trend and stably maintained their original M state
with no increased E signature expression after replating
(Figure 1B, Supplementary Figure 1B). As expected,
suspension culture of E clones (E1 to E6) resulted in
nearly no visible mammospheres compared to the M clones
(Supplementary Figure 1A), consistent with anoikis of E
cells [36] or quiescence upon detachment. Intriguingly,
replating of each of the 6 tested E clone-derived cultures as
well as each of the 11 mostly epithelial HP mammosphere
cultures resulted in a viable readhesion culture that could
be analyzed by gene expression analysis (Supplementary
Figure 1A). In contrast to M clones, all biological replicates
of 2 out of 3 tested E clones and all tested (epithelial) HP
cell line replicates reached a stable intermediate E/M state
due to partial loss of E signatures and gain of M signatures
which is consistent with partial EMT after replating.
Taken together, these data suggested that HMLER
M clones reside in a rather stable M state and the partial
MET of M clones in suspension was only transient. By
contrast, HMLER E cell lines consistently generated
stable intermediate E/M populations upon suspension
and replating. Thus, EMT was inevitable upon placing in
suspension culture and replating of HMLER cells, which
resulted in an increase of heterogeneity in E cell lines but
loss of heterogeneity in M cell lines.

analyses of HMLER M clones that showed stable RNA
expression of M signatures and absence of any E genes,
while in HMLER E clones the majority cells individually
co-expressed both E and M signatures indicating a hybrid
E/M state [12]. To ensure that this finding was not due to
potential clonal artifacts, we generated a lentiviral dual
fluorescent reporter vector, designated CDH1 reporter,
using the promoter for the gene CDH1, which encodes the
epithelial adhesion protein E-Cadherin to drive expression
of the red fluorescent mCherry (mCh) that reports the E
state. The yellow fluorescence protein YFP expressed
constitutively served as a positive control for presence of
the reporter vector (Supplementary Figure 2A, Methods).
As expected, CDH1 reporter-transduced mixed HP
populations contained typical E colonies that co-expressed
mCh and YFP, while cells classified as M cells based on
morphology only expressed YFP (Figure 2A). Using FACS
we then generated non-clonal trackable YFP-positive E and
M cell lines by sorting for mCh+/YFP+ cells and mCh–/
YFP+ cells (Supplementary Figure 2B) corresponding
to CD24+ epithelial E_YFP+ and CD24− mesenchymal
M_YFP+ cell lines, respectively. As expected, all E_YFP+
and M_YFP+ cell lines resembled HMLER E and M
clones, respectively, in CD24-expression (Figure 2B) and
morphology (Supplementary Figure 2C).
Next, we sorted individual YFP+ cells from the
E_YFP+ and M_YFP+ cell lines passaged as adhesion
cultures for single cell qPCR expression analysis of 9
E-specific and 11 M-specific marker genes. Results were
plotted in an E/M state space (Figure 2C) combining the
cell state specific markers (Methods). qPCR analysis of
E_YFP+ cells confirmed the previously observed E/M
heterogeneity of E5 and non-clonal HP cell lines [12]
since 11 of 19 evaluable E_YFP+ cells exhibited a hybrid
E/M signature (58%), with four cells (21%) exclusively

Mesenchymal HMLER cell lines do not exhibit
E/M heterogeneity when examined by single cell
analysis
The population level gene expression data were
consistent with our previous observations in single cell

Figure 2: Abundance of hybrid E/M cells in E versus M HMLER cell lines. (A) Overlay fluorescent microscopy shows

heterogeneous HP cells transduced with dual reporter construct (CDH1-reporter) where red indicates the E state by active CDH1 promoter
visualized by mCherry and green indicates live and transduced cells by active SV40 promoter shown by YFP (40× magnification). (B)
FACS profiles of αCD24-stained non-transduced and CDH1 reporter transduced stable E and M cell lines. (C) Single cell qPCR analysis
shows E/M state space representation of E5, M4, E_YFP+, and M_YFP+ cell populations using aggregate expression of 9 E genes and 11
M genes (see Methods). Note that E cell lines contain mostly hybrid E/M cells and M cell lines show complete EMT in most cells. Data
are representative for both independent experiments using different reporter cell lines.
www.oncotarget.com
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expressing M genes and four cells exclusively expressing
E genes (Figure 2C). By contrast, only one (5%) of the
20 evaluable single M_YFP+ cells showed a hybrid E/M
signature, none expressed E genes, while all others (95%)
exclusively expressed M genes, and thus resembled the
M5 (Figure 2C) and M4 clones [12]. Thus, single cell
analysis of nonclonal HMLER E and M reporter cell
lines showed similarity with the respective clonal cell
lines by sharing morphology, presence or absence of E/M
heterogeneity, CD24 expression, and hybrid E/M status.

The presence of E cells in suspension cocultures,
high E cell plasticity and absence of MET plasticity of
M cells suggested that cooperation of E and M cells can
facilitate survival, persistence, as well as readhesion of
pre-existing E cells by cooperation with M cells indicating
E cells being MICs. On the other hand, the findings could
not exclude the possibility that coculture with E cells
generates a suitable microenvironment for MET of M cells
with M cells being MICs.

Coculture of E and M cells results in persistence
of E cells by suppression of epithelial plasticity

Coculture with M cells allows for persistence of
E cells during suspension culture and replating

To identify whether E or M cells gave rise to the
CD24+/CD44– (E) subpopulation under coculture
conditions in suspension, we utilized the genetically YFPlabelled E_YFP+ and M_YFP+ cell lines. Consistent with
single cell analyses (Figure 2) and with observations in
HMLER E clones and freshly sorted CD24+/CD44– (E)
cells from HP cells (Figure 3A), E_YFP+ cells were
highly plastic, as they converted to the CD24–/CD44+
(M) state after mammosphere suspension culture. Of
note, during suspension-induced EMT E_YFP+ cells
lost YFP expression. By contrast, within the same period
of two weeks M_YFP+ cells retained YFP, and stably
remained in their CD24−/CD44+ (M) state (Figure 3D)
consistent with absence of plasticity in M clones. E and M
cocultures were generated by sorting 1:1 ratios of E_YFP+
cells and M_YFP+ cells or in either combination with
the non-fluorescent E5 and M5 clones under suspension
mammosphere conditions (Figure 3C, 3D, Supplementary
Figure 3B, 3C). According to our observations of
cooperation (Figure 3A), all E and M cell coculture
combinations consistently contained a small distinct
E cell subpopulation and both E and M cells expressed
YFP in dissociated suspension cultures (Figure 3D).
Moreover, all combinations of E and M cell cocultures
showed a synergistic increase of number of mammosphere
formed (Figure 3C) and of cell numbers in dissociated
mammosphere (Supplementary Figure 3B) by at least
3-fold or 5-fold, respectively, relative to projected additive
effect using numbers from E or M cell monocultures.
Tracking the origin of E cells in cocultures of E_
YFP+ and unlabeled M5 cells exhibited an increased
number of YFP+ mammospheres (5-fold) and YFP+/
CD24+/CD44− (E) cells (30-fold) compared to E_YFP+
suspension culture alone (Figure 3C, Supplementary
Figure 3B). In these cultures, 83% of all E cells were found
to express YFP (Figure 3D, Supplementary Figure 3C).
Conversely, in mammosphere cocultures of M_YFP+ with
E5 cells no E cells were YFP+ (Figure 3D, Supplementary
Figure 3C). This suggested that during suspension
mammosphere culture the E subpopulation was derived
from pre-existing, persisting E cells and not by MET from

When subjected to suspension culture, HMLER
E (CD24+/CD44–) populations either undergo anoikis
or EMT and become CD24–/CD44+ (M) cells, while
HMLER M (CD24–/CD44+) cells are not plastic and
do not undergo MET [12]. Thus, it remains unclear how
E cells can form macrometastases at a distant site after
a prolonged detachment phase. To investigate whether
cooperation between cells could be responsible for
survival of E cells after suspension and replating, we
examined cocultures of E and M HMLER cells. Using
flow cytometry, E and M cells from a heterogeneous
HMLER cell line were sorted and cocultured in a 1:1 ratio
under suspension mammosphere conditions for two weeks.
After dissociation of mammosphere cultures, staining,
and flow cytometry, intriguingly we detected a small but
consistently distinct CD24+/CD44– (E) subpopulation in
these cocultures (Figure 3A). By contrast, no E cells but
only pure M cell populations were detected when E or
M cells were cultured by themselves (Figure 3A). Even
increasing the seeded cell number from 2,000 to 16,000
cells (Supplementary Figure 3A) did not induce an E cell
subpopulation in the M clone-derived mammospheres,
again suggesting the absence of spontaneous MET in M
monocultures. Consistent with our previous findings of
E and M cooperation [12], the 1:1 coculture resulted in
increased total cell numbers compared to monoculture
of E cells (more than 60-fold), M cells (more than 20fold), and more than 16-fold compared to HP cultures
(Figure 3B). Replating suspension cultures to adhesion
culture, staining, and flow cytometry analysis confirmed
that the E population found in cocultures was stably
maintained through the two weeks of each suspension
culture and the subsequent replating, while it remained
absent in replated mammospheres of E or M monocultures
(Figure 3A, Supplementary Figure 3A). Intriguingly,
in the heterogeneous HP cells that were mostly E cells
(72%) but even under adhesion culture contained a
pre-existing M subpopulation of 18%, we consistently
detected an E subpopulation after suspension and replating
(Supplementary Figure 3A) suggesting that cooperation
could occur also in the mixed HP cell population.

www.oncotarget.com
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M cells, consistent with the hypothesis of an irreversibly
transdifferentiated state of HMLER M cells.
When tracking the origin of M cells in suspension
in cocultures of M_YFP+ cells with E5 cells, we

observed an increase of YFP+ mammospheres (3-fold)
and of YFP+/CD24−/CD44+ cell (18-fold) numbers
compared to M_YFP+ cells cultured alone (Figure 3C,
Supplementary Figure 3B). Nearly all CD24−/CD44+

Figure 3: Coculture with M cells facilitates E cell persistence and inhibition of EMT in suspension. (A) After suspension

mammosphere culture condition (MS), E cells are only found in mammospheres derived from E/M cell cocultures but not from E or M
monocultures. Quantitative flow cytometry profiles of sorted E (CD24+/CD44−), M (CD24−/CD44+) subpopulations and unselected HP
cells cultured alone or together (1,000 cells per cell-type) were grown as mammospheres for two weeks, and subsequently replated to
adhesion for another week. (B) Total surviving cell numbers from dissociated mammosphere cultures shown in (A). (C) Total number of
YFP- and YFP+ mammospheres per well after two weeks suspension of E/M cocultures and E or M monocultures as assessed by flow
cytometry. (D) Flow cytometry analysis of dissociated and αCD24/αCD44-stained mammosphere cultures of E/M cell cocultures from
(C) either gated for live cells (YFP+ and YFP−) or live YFP+ cells (YFP+) with each column representing the same sample. Note that no
YFP+/CD24+/CD44− cells were found in E/M cocultures with M_YFP+ cells, and no YFP+/CD24−/CD44+ cells were detected in E/M
cocultures with E-YFP+ cells. All data are representative for experiments performed in biological duplicates.
www.oncotarget.com
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(M) cells were YFP+ in cocultures of E5 and M_YFP+
cells (97%). But surprisingly, no M cells were found to be
YFP+ in cocultures of E_YFP+ and M5 cells (Figure 3C,
Supplementary Figure 3C). Hence, the highly plastic
E cells did not convert to the M state by EMT when
cocultured in suspension with M cells. Together these data
suggested that the mechanism of cooperation between E
and M cells involves inhibition of E cell plasticity and is
accompanied by proliferation of M cells.
Besides the independent validation of absence of
plasticity of HMLER M cells, cell tracking revealed that
the increase of both E cells and M cells in suspension
coculture of E and isogenic M cells is not a consequence
of sequential EMT and MET at the single cell level but
consistent with mutual E and M cell cooperation [37]
which stimulated M cell expansion and persistence of E
cells.

can be aggregates of heterogeneous cell types has
gained acceptance [39, 40]. If cell contact with M cells
produced E cells persistence, we expected that E and M
cells would form heterogeneous aggregates in suspension
mammosphere cultures. To test this hypothesis, we
transduced HP cells with a vector to constitutively express
GFP (PCMV-YFP) or mCherry (PCMV-mCh), freshly sorted
200 individual mCh+/CD24+/CD44− (E) cells together
with 200 individual YFP+/CD24−/CD44+ (M) cells,
and cocultured them under mammosphere conditions.
We then imaged suspension cultures after two days.
Indeed, we observed heterogeneous multicellular mCh+/
YFP+ aggregates (Figure 4C), suggesting that E and M
cells exhibit affinity to each other even at very low cell
densities and that aggregation with M cells may inhibit
detachment-induced anoikis of E cells.

M signatures predict more favorable patient
outcomes than E signatures in basal breast cancer

Soluble factors and cell-cell contact mediate
cooperation of E and M cells

Finally, we examined if recent findings in mouse
models of M cells not being MICs [28, 28, 30, 31] and the
HMLER cell tracking results presented here in support of
the cooperation metastasis model are reflected in clinical
data. Since metastasis is linked to poor patient survival our
in vitro data would suggest that in patients the E signatures
predict worse outcomes than M signatures. To test this
hypothesis, we analyzed the predictive power of E and M
signature expression for relapse free survival (RFS) and
overall survival (OS) of up to 1764 or 626 breast tumor
patients, respectively, by applying the Kaplan-Meier
plotter (KMP) online tool [41, 42].
Using previously defined E- and M-specific HMLERderived gene expression signatures (Supplementary Figure
4A, Supplementary Table 2, Methods) in the complete
KMP breast cancer database, we found that the M_HMLER
signature was significantly associated with favorable patient
outcomes in terms of OS (HR = 0.7, p < 0.05) and RFS (HR
= 0.74, p < 0.001). By contrast, the corresponding E gene set
based on the E_HMLER signature predicted significantly
poor outcomes (HR[OS]=1.88, HR[RFS]=1.81, p<0.0001)
(Figure 5A). To ensure that these findings were due to
particularities of the HMLER-specific gene sets, we rerun
the analysis for four additional gene sets for the E and
M signatures, derived independently from breast (Taube
HMLE, Tan cell lines) and lung (Loboda) cancer cell lines
[43, 49, 64] and different tumor types (Tan tumor) [49]
(Methods and Supplementary Table 2). These alternative
M gene signatures corroborated the above findings and
indicated more favorable OS (between HR = 0.8 and 0.87)
(Figure 5B), while the alternative E gene sets consistently
predicted worse OS (between HR = 1.21 and HR = 1.52).
However, the differences between the corresponding E and
M signatures for these four additional E and M signature
sets had overlapping 95% confidence intervals. Consistent
with the reported stemness of the intermediate E/M state

We reasoned that this mutual cooperation in
suspension of HMLER E and M cells could either be
mediated by soluble paracrine factors released by the
partner cell type or by direct cell-cell contact. Thus, we
cultured E cell lines (E5 and HP cell lines with ~90% and
~72% E cells in adhesion, respectively) and pure M cells
in the presence of conditioned medium from adherent
M4 cells (M4_cm) or from adherent E5 cells (E5_cm)
(Figure 4A). Suspension culture of M4 cells with E5_cm
led to an increase of total mammospheres and almost
resembled the mammosphere increase observed by
coculturing E and M cells. This suggested that soluble
E factors can mediate the effect of coculture towards
increased mammosphere formation and proliferation of
M cells. By contrast, there was no stimulatory effect of
M4_cm on mammosphere formation of E cells (neither in
E5 nor HP cell lines) (Figure 4A).
Consistently, cell-type analysis by CD24 and
CD44 phenotyping of E or HP-derived mammospheres
cocultured with the conditioned medium M4_cm showed
no increase in E cell numbers (Figure 4B). As expected,
no CD24+/CD44− E cells were found in dissociated
mammospheres of M4 cells cultured with E5_cm or M4_
cm, again pointing to the absence of MET and the stably
transdifferentiated state represented by the M clones.
Thus, soluble paracrine E factors may be able to mediate
the cooperation towards increased proliferation of M
cells in suspension but do not induce MET, whereas no
paracrine M cell factors could support persistence of E
cells in suspension (Figure 4B).
Next, we investigated cell-cell contact as possible
mechanism for the cooperation through which M cells
could confer persistence to E cells. While originally it
had been proposed that mammospheres are clonal [38],
more recently the picture that mammosphere actually
www.oncotarget.com
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[12] the combined presence of E and M signatures also
predicted poor outcomes (between HR = 1.14 and HR =
1.85, Figure 5B), resembling the outcome predicted by the
E signatures.
By induction of EMT in HMLE cell lines using
siCDH1, SNAI1, TWIST, and GSC overexpression,
or TGFβ treatment [43] Taube et al. had generated
five different corresponding E and M signatures
(Supplementary Table 2). An older KMP-database
version significantly predicted favorable OS and RFS
in breast cancer patients for these Taube M signatures
alone (between HR = 0.58 and HR = 0.66, p < 0.017).
Outcomes associated with M signatures were consistently
better (between HR = 0.58 and HR = 0.63) than their
corresponding E signatures alone (between HR = 0.76
and HR = 1.4) or E signatures in combination with
M signatures (between HR = 0.73 and HR = 0.88,
Supplementary Figure 4C). Together, these observations
are in agreement with the hypothesis of cooperation

between E and M cells and of E cells being highly plastic
and having potentially MIC character.
To determine in which breast cancer subtype
enrichment of the M signatures was associated with better
outcomes and induction of complete EMT may possibly
even have therapeutic benefit we used the St. Gallen
criteria classification of the KMP and divided the tumors
in the KMP database into the four canonical intrinsic
subtypes: the ER-positive luminal A and luminal B tumor
subtypes, the ER-negative basal and the HER2-positive
subtypes [41, 44]. Intriguingly, in the basal breast cancer
subtype we observed that all five M signatures consistently
predicted more favorable outcomes (between HR = 0.36
and HR = 0.72), while their corresponding E signatures
predicted poor outcomes (between HR = 1.75 and HR =
2.7). These differences between E and M signatures were
significant within a 95% confidence interval for four out
of the five signatures tested (Figure 5C). The same trend
of E signatures predicting worse outcomes, albeit not
within 95% intervals, was observed for the five different

Figure 4: The role of soluble factors and direct cell-cell contact for synergistic effect of E/M coculture in suspension.

(A) Relative numbers of mammospheres from HP, E5 or M4 clone cells after treatment with conditioned medium (CM) of adherent E or
M cells or E/M coculture. Average of data performed in duplicates is shown. (B) Quantitative flow cytometry of the four different CD24/
CD44 subpopulations from (i) in adhesion grown source cells and from (ii) cells found in dissociated mammospheres after mono- and
coculture of E and M cells with or without CM. (C) Spontaneous heterogeneous aggregates of freshly sorted CMV-driven mCherrylabelled CD24−/CD44+ (M) and CMV-driven GFP-labelled CD24+/CD44− (E) cells after 2 days culture under mammosphere conditions.
www.oncotarget.com
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Taube EMT signatures in the basal subtype in an older
database (Supplementary Figure 4C). In none of the
other breast cancer subtypes was a consistent difference
for outcomes between tumors with predominant E and
M signatures observed (Figure 5C); in the luminal A
and B subtypes both E and M signatures were associated
with poor OS, while in the HER2+ subtype four of the
five tested E signatures (between HR = 1.67 and HR =
2.1) were also associated with worse outcomes than M
signatures (between HR = 0.33 and HR = 0.75), which
was significant within a 95% confidence interval for two
of the five tested E and M signature pairs.
In conclusion, patient data show that E signatures
are mostly associated with worse outcome than M
signatures in breast cancer, thus supporting the hypothesis

that E cells rather than M cells represent the MICs in
breast cancer, particularly in basal breast cancer.

DISCUSSION
Most life-threatening macrometastases in breast
cancer are epithelial and resemble the primary tumors.
However, it is still unclear how anoikis-prone E cells
reach distant metastatic sites after detachment, and
whether M or E represent the MICs that give rise to the
E metastases. Using the basal-like breast cancer cell
line HMLER, we present here in vitro evidence that
MICs may originate from cells in the epithelial state
and that mutual cooperation with M cells can support
the survival and persistence of a pre-existing CD24+/

Figure 5: M signatures indicate more favorable patient outcomes than E signatures in basal breast cancer. (A) Kaplan

Meier plots for RFS and OS associated with HMLER_E and HMLER_M signatures in breast cancer. Patient numbers, hazard ratio (HR),
95% confidence intervals, and logrank p-values (P) for respective signatures are indicated. (B) HR for OS associated with E, M and E/M
composite signatures derived from different sources in breast cancer (626 patients). Asterisks indicate signatures predicting OS with p
values < 0.05. (C) HR for OS associated with different E and M signatures in different breast cancer subtypes. Analyzed patient numbers
are indicated in brackets.
www.oncotarget.com
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CD44– (E) subpopulation and lead to E cell proliferation
in suspension culture. We further provide evidence
that M cells can reside in the stable (irreversible) M
transdifferentiated state such that they are unlikely to
undergo MET but rather function to aid in stabilizing the
E population by suppressing their anoikis and plasticity,
i.e., their inherent potential to undergo EMT. Thus, our
data are consistent with a series of recent mouse studies
demonstrating that M cells do not give rise to metastasis
by MET [6, 30, 31, 33, 34]. Consistent with our in vitro
data, clinical data show that M signatures predict better
outcomes in breast cancer patients than E signatures,
particularly in basal breast tumors. Together, these data
support the cooperation metastasis model in which E cells
are the MICs.
In our previous study we had determined that
stemness was associated with the intermediate E/M state
for most breast cancer subtypes as well as for the HMLER
E and M cell lines. However, it remained unclear whether
stemness depended upon individual stem-like hybrid E/M
cells or on the mixture of M and E cells which would
suggest E-M cooperation [12]. By analyzing individual
clonal E and M populations alone as well as E and M
mixtures, and reporter cell lines, our present data suggest
the existence of two different types of hybrid E/M cells:
(i) hybrid E/M cells derived from M cells which were
instable and underwent EMT when allowed to readhere,
and (ii) hybrid E/M cells derived from E cells which were
stable and found in the majority of tested E population
(Figure 2C). These observations reinforced our previous
notion that HMLER E cells display much more plasticity
along the E-M axis than M cells, and that E cells are more
likely to give rise to heterogeneous E and M signatures in
HMLER cell populations with stemness properties [12].
We conclude that at least in HMLER cells mainly E cells
have the potential to give rise to cooperating E and M
populations. If that holds true for breast cancer in general,
then pre-existing and residual E cells from the original
tumor would be necessary to produce at a metastatic site
the same epithelial heterogeneity as in the primary tumor.
The observation that in breast cancer patients in general,
and particularly in the basal subtypes, better survival
correlates with M signatures supports this notion, and
is in agreement with findings of other reports that used
different and smaller databases [43, 49].
Our results on the absence of complete MET at the
single cell level in HMLER cells stand in sharp contrast
to the popular assumption that metastasis is caused by
cellular plasticity of individual highly aggressive cancer
stem cells [13, 45] that undergo EMT, thereby generating
more aggressive cell types [4, 5]. According to this
perspective, M cells resulting from EMT are considered
the MICs and will have to eventually undergo MET, in
accordance to the sequential metastasis model [17, 46].
Our results suggest that pre-existing E cells acting as
MICs, generate the adherent E population after replating
www.oncotarget.com

following a suspension phase and represent the majority of
cells in our HMLER model; however, we cannot exclude
the occasional existence of M MICs and of spontaneous
METs that may be triggered by rare mutations. In
support of our findings, we observed that EMT was
nearly inevitable for individual E HMLER cells once
detached from the adhesion state, which may also apply
to metastatic E cells leaving the primary tumor (Figures 1,
2). Furthermore, EMT even occurred in M clones that had
transiently undergone a partial MET (Figure 1B). Thus,
any spontaneous partial MET would be overridden by the
default EMT process upon detachment and readhesion.
Finally, although our data suggest that MET at the single
cell level may be unlikely, the migratory and less adherent
nature of M cells in proliferating mixed populations
may lead to an enrichment of E cells and an apparent
(population level) MET in certain metastatic solid tumors.
A few but important experimental differences to
earlier studies [4, 13, 45] may underlie the discrepancy
between previous reports and our results. First, we have
not only used a single cell line but a series of single cellderived clones as well as stable reporter cell lines, which
has enabled us to identify the individual E and M cell
fate (Figure 1B). Second, previous studies [4, 5, 45] used
mixed E and M populations for sorting. However, mixed
cell populations (as shown for HMLER cells) may still
contain two types of CD24−/CD44+ (M) cells, pure M
cells originated from completed EMT, as well as stemlike hybrid E/M cells which may have been directly and
recently derived from the highly plastic E cells [12]. To
overcome this bias, we used here clonal populations or
stable M reporter cell lines that had undergone complete
EMT and only contained pure M cells as determined
by single cell analysis (Figure 2C). Third, to track cell
fates we cultured cells under suspension mammosphere
conditions that allowed nearly clonal expansion that
mimic the metastatic process that is thought to start
from few cells. By contrast in other studies [4, 5, 45]
large numbers of E versus M cells were sorted directly
into highly charged 2D adhesion plastic dishes which
favors an apicobasal polarity and adhesion as is needed
for the E phenotype, potentially preventing complete
EMT of “contaminating” E cells. Along the same lines,
it has been suspected that 2D adhesion cultures do not
accurately replicate cancer cell behavior in patients, and
that 3D or mammosphere suspension cultures better reflect
tumor heterogeneity [38, 47, 48]. Thus, the controversial
experimental results may be explained by our experimental
conditions that model metastasis by detachment of
tumor cells, a prolonged suspension culture phase, and
readhesion as opposed to experimental conditions that
relied on cells exclusively cultured in adhesion.
Given that we did not observe plasticity in the sense
of MET in vitro, dominance of EMT upon detachment
and readhesion as well as the significant association
of M signatures with favorable patient survival in
20027
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basal tumors, it could be assumed that complete EMT
in individual breast-derived cells may represent an
irreversible transdifferentiation into a non-tumorigenic
state and associated tumor microenvironment, as opposed
to a reversible transition into aggressive cells. The
tendency of the epithelial HMLER cell lines to undergo
transdifferentiation towards the M state upon detachment
may thus explain their low tumorigenicity and absence
of metastasis in mouse models [49]. Even upon normal
passaging for more than 15 passages, HMLER cells tended
to spontaneously undergo EMT (Supplementary Figure 1A),
and thus EMT of E populations and tumors may be
inevitable during development. Indeed, a combination
of experimental data and mathematical modelling
demonstrated that e.g. the transcription factor GRHL2
stabilizes the intermediate E/M state and predicts poor
outcomes in breast, kidney, lung, and liver cancers [50].
Mechanistically, we present evidence at the cellular
level that cooperation is not mainly mediated by soluble
factors but also by direct cell-cell contact of pre-existing
HMLER E cells and stably transdifferentiated M cells
(Figure 4C). Thus direct E-M cell contact may prevent
EMT of E cells. This is in contrast to studies showing
that mammospheres are clonal [38], but consistent with
several recent studies demonstrating non-clonality of
mammospheres [40]. Our results are also in agreement
with observations that circulating tumor cell (CTC)
clusters are substantially more tumorigenic than individual
CTCs [51], and that fresh patient-derived tumors are best
propagated in mice as clusters. More studies are needed to
understand if E and M cell clustering can prevent EMT in
primary tumors, and which molecular mechanisms mediate
the clustering. Furthermore, our data on cooperation of E
cells with the transdifferentiated M cells support studies
suggesting that clustering with stromal cells of the tumor
microenvironment, such as mesenchymal stem cells [52,
53] or fibroblasts [54, 55] can promote outgrowth of
metastatic breast cancer cells.

Mammospheres (MS) were generated as described
earlier [38]. Briefly, adherent cells were trypsinized, and
(unless otherwise stated) cell numbers of 10,000 to 20,000
cells/ml were either flow cytometry-sorted or pipetted into
ultra-low attachment (ULA) plates (96 well plates, 100ul
volume, Corning). Mammospheres were cultured for 2–3
weeks in DMEM/MEGM supplemented with 1× B27
(Life Technologies) and 1% methylcellulose (viscosity
4,000cP, Sigma) in biological duplicates. E/M cocultures
were always generated from equal numbers of E and M
cells, and compared to equal total numbers of E or M
monocultured cells. Mammospheres were counted by eye
with a 4x or 10x objective. For replating mammospheres
to adhesion cultures, 50% of dissociated non-stained
mammosphere suspension cultures was transferred into
normal adhesion culture conditions and analyzed by
quantitative flow cytometry after one week. For gene
expression arrays replated cultures were analyzed after 6
hours to 10 days (for HP cells and M clones) and after 2–3
weeks (E clones) as indicated in the text.

Sorting and single cell qPCR analysis
Single cell analysis was performed as described
before [12]. Briefly, live single cells of equal FSC/
SSC morphologies within the middle of the respective
fluorescent gates were sorted directly into 96 well-plates.
Wells contained Taqman primers and Cells Direct One-step
RT-PCR and pre-amplification mix (Life Technologies)
followed by RT and 18 cycles of preamplification in
a GeneAmp PCR System 9700 instrument (Applied
Biosystems) according to the Fluidigm single cell protocol.
Gene expression was analyzed on a BioMark instrument
using 48.48 Dynamic Array IFC chips (Fluidigm) and
Taqman primers (Applied Biosystems).
Single cell data were analyzed similar as described
previously [12]. Briefly, measured Ct values were
transformed into linear expression values according to
Fluidigm’s single cell application protocol. Expression
data for every E gene was normalized to the value of the
maximum measured for the same gene in a simultaneously
analyzed 100-cell samples of adherent E cells (HP and E4
cells) and divided by 100, while M genes were normalized
for maximum measured 100-cell value in adherent M5
cells. To plot single cell gene expression values into the
E/M state space, normalized expression values per single
cell were averaged for 9 E genes (CDH1, EPCAM, KRT5,
LCN2, S100A8, S100P, SLPI, TP63, TNFSF10/TRAIL)
and 11 M genes (ABCA6, AR, CDH2, DCN, FN1,
PCOLCE, SNAI1, VIM, WNT5A, ZEB1, ZEB2).

MATERIALS AND METHODS
Cell culture
HMLER cells are primary human mammary
epithelial cells (HMECs) transformed to carcinoma
cells through the introduction of SV40 large T and Ras
oncogene [35]. HMLER cells were kindly provided
by Robert A. Weinberg (Whitehead Institute). Parental
HMLER (HP) cells, single cell-derived epithelial (E1
to E6) and mesenchymal HMLER clones (M1 to M5)
were described previously [12]. All HMLER-derived cell
lines were passaged in adhesion under serum-free culture
conditions in a 1:1 mix DMEM (Life Technologies)/
MEGM (Lonza). Conditioned medium (CM) was
harvested from adherent nearly confluent E5 and M4 cells
and separated from suspended cells by centrifugation.
www.oncotarget.com

Gene expression arrays and principal component
analysis
RNA of cells grown in adhesion was isolated
by lysing PBS-washed cells by addition of Trizol (Life
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Technologies) to the adherent cells in the dish, as
detaching of cells before Trizol resulted in substantial
RNA degradation. RNA was purified according to the
manufacturer’s instructions. Gene expression analysis
was performed essentially as described [12]. Briefly,
50 ng to 100 ng RNA was labeled using the one color
Low Input Quick Amp Labeling Kit (Agilent), and
labeled probes were run on Human 4 × 44 K Microarrays
(Agilent) according to the manufacturer’s instructions.
Data were analyzed with Genedata Analyst 7.0 (Genedata,
Basel, Switzerland). Data normalization was performed
using central tendency followed by relative normalization.
Principal Component Analysis (PCA) of gene expression
array data was performed using the indicated 150 most Eand M-specific signatures by using a covariance matrix in
GeneData Analyst 7.0.
The complete microarray dataset shown in Figure 1
has been deposited in NCBI’s Gene Expression Omnibus
and is accessible through GEO accession numbers
GSE66527 (adherent cells and mammospheres) and
GSE70279 (replated cells). RNA of adhesion cultures was
derived from five different freezing passages of HP cells,
five HMLER M clones and six different HMLER E clones
(biological duplicates). RNA of readhesion cultures was
derived from HP cells (10 biological replicates from four
different passages), and three different E clones and M
clones (biological duplicates).

the promoter reporter construct itself by using the
constitutively active SV40 promoter driving expression of
yellow fluorescent protein (YFP). Using the commercially
available pLenti6/V5-D-TOPO vector (Thermo Fisher)
as a base, we exchanged the CMV promoter with the
human CDH1 promoter (PCDH1). A sequence of 1122 bp
of the human CDH1 promoter region (-1178 through -57
upstream of the initiator methionine) was PCR amplified
using 293T cell genomic DNA using the forward primer
(5′ agatcagcctcggcaacatagtg 3′) and reverse primer (5′
gctggagcgggctggagtctga 3′). The CDH1 promoter drives
the expression of a 711 bp mCherry open reading frame
[60]. The blasticidin ORF of the original vector pLenti6/
V5-D-TOPO was replaced by the 720 bp long YFP ORF
[61], so that YFP is constitutively expressed by the PSV40
promoter of the original vector.
Transduction of heterogeneous HP cells was
performed using the Virapower Lentiviral Expression
Systems kit (Life Technologies). Briefly, the CDH1mCherry reporter construct together with pLP1, pLP2,
and pLP/VSVG was transfected into 293FT cells. HP
cells were then transduced with the virus-containing
supernatant, expanded, and after cell sorting the two
YFP-positive cell lines (mCherry-positive E_YFP+ and
mCherry-negative M_YFP+) were derived and expanded.
Single cell qPCR data (Figure 2) and cytometry data
(Figure 3) shown are representative for two independently
derived E_YFP+ and M_YFP+ cell lines.

Staining and flow cytometry analysis

Microscopy

Single cell suspensions of trypsinized adherent
growing cells or dissociated mammospheres were stained
with antibodies (αCD24-PE: clone ML5, αCD44-FITC
or αCD44-APC: clone G44–26, BD-Biosciences) diluted
1:25 in DMEM supplemented with 2% FBS and 25 mM
HEPES. Flow cytometry data acquisition was performed
on a FACSAria II SORP (Becton Dickinson) and analyzed
with FlowJo software (Tree Star, vX.0.6). To determine
cutoffs for the CD24/CD44 quadrants for any cell line,
simultaneously stained heterogeneous HP cells (expanded
in adhesion) were included as a reference. Relative cell
numbers in mammosphere cultures within an experiment
were determined by ‘quantitative flow cytometry’
assessing cell numbers in the same volumes and same
time. All data shown are representative of at least two
experiments performed in biological replicates.

Cells were imaged on a DM IL LED instrument
(Leica) with a DFC345 FX camera or on a DeltaVision
Core instrument (GE Healthcare).

Kaplan-Meier survival analysis
The ‘Kaplan-Meier Plotter’ (KMP) online tool
(kmplot.com) was used with either the 2017 breast
cancer dataset (1764 and 626 patients for ‘relapse-free
survival’ (RFS) and ‘overall survival’ (OS), respectively).
According to the KMP tool breast cancer (all BC subtypes)
is classified into four clinically relevant intrinsic subtypes
based on the St. Gallen criteria using bimodal expression
of estrogen receptor (ER, ESR), expression of HER2
(HER2), and the proliferation marker Ki67 (MKI67)
into luminal A (ESR+, HER2-, MKI67low), luminal B
(ESR+,HER2-, MKI67high and ESR+, HER2+), basal
(ESR-, HER2-) and HER2+ (ESR-, HER2+) patients
[41, 42]. Hazard ratio (‘HR’, within 95% confidence
intervals) and logrank p-values (Cox’ proportional hazard
ratio analysis) for survival of breast cancer patients
[41] was determined by the mean expression of the
respective gene signatures (Supplementary Tables 1 and 2)
[12, 43, 62, 63]. The ‘autoselect best cutoff’ option [64] was
used for subdividing gene expression in primary tumors by

Generation of fluorescent E and M reporter cell
lines
For tracking origin of E and M cells, we generated
a lentiviral dual fluorescent CDH1-promoter reporter
vector (pLenti6-PCDH1-mCherry_PSV40-YFP). The 8.6kb
long CDH1-promoter reporter vector could track CDH1
transcriptional activation by driving fluorescent mCherry
expression and simultaneously showed presence of
www.oncotarget.com
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median, quartile or tertile expression, and ‘JetSet best probe
set’ [44] option was used to assess HR, 95% confidence
intervals and logrank p-values for patient survival.

cells; HR: hazard ratio; EMT : epithelial-to-mesenchymal
transition; KMP: Kaplan-Meier Plotter; M : mesenchymal ;
MET: mesenchymal-to-epithelial transition; MS:
mammospheres; OS: overall survival; PCA : principal
component analysis; RFS: relapse-free survival; YFP:
yellow fluorescent protein.

Gene signatures
All E and M gene signatures were derived by
comparing epithelial versus mesenchymal cell lines
cultured in vitro or in mice, and contained the 24
(Supplementary Table 1), 50 (Supplementary Table 2) or
150 [12] most differentially expressed genes. E_HMLER
and M_HMLER signatures were defined from HMLER E
and M clones as described before [12]. The Taube HMLE
E and M signatures were derived from HMLE cells
induced to undergo EMT by transduction with siCDH1,
SNAI1, TWIST, GSC, or treatment with TGFβ, or from
the overlap respective overlap (Taube HMLE) [43]. E_
Tan and M_Tan signatures were based on breast cancer
cell lines or tumors [63], and E_Loboda and M_Loboda
signatures were derived from lung tumors [62].
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CONCLUSIONS
To our knowledge the intriguing consequence of
complete EMT irreversibly converting E to M cells, hence
eliminating MICs has not been explored yet. It is generally
assumed that tumors become gradually more aggressive
over time accumulating conversion into M cells. Hence,
much effort went into exploring the inhibition of EMT and
inducing MET as a therapeutic strategy [56, 57]. This may
be detrimental in view of the findings presented here where
enrichment for M signatures are associated with better
outcomes and E signatures with worse outcomes in breast
cancer. It is noteworthy that basal tumors are considered
more mesenchymal tumors than luminal tumors. In support
of the new notion that the M state is less aggressive,
and thus, that EMT does not necessarily result in more
aggressive tumors, basal breast cancer patients have a
indeed a higher pathological response rate and better long
term survival than luminal breast cancer patients, albeit
worse short term outcomes [58, 59].
Our in vitro and patient analysis suggest that tumorspecific therapeutic induction of complete EMT may have
a long lasting clinical benefit in basal (triple-negative)
breast cancer patients due to a potential irreversibility of
EMT of individual cells and corresponding inhibition of
epithelial metastases. Particularly patients with basal ERnegative breast tumors have an unmet clinical need due to
absence of targeted therapies for this subtype. Given that
M signatures are associated with favorable outcomes these
patients may benefit from EMT induction.
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